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Abstract
Background: We and others have shown that one of the mechanisms of growth regulation of
small cell lung cancer cell lines and cultured pulmonary neuroendocrine cells is by the binding of
agonists to the α7 neuronal nicotinic acetylcholine receptor. In addition, we have shown that the
nicotine-derived carcinogenic nitrosamine, 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK),
is a high affinity agonist for the α7 nicotinic acetylcholine receptor. In the present study, our goal
was to determine the extent of α7 mRNA and protein expression in the human lung.
Methods: Experiments were done using reverse transcription polymerase chain reaction (RT-
PCR), a nuclease protection assay and western blotting using membrane proteins.
Results: We detected mRNA for the neuronal nicotinic acetylcholine receptor α7 receptor in
seven small cell lung cancer (SCLC) cell lines, in two pulmonary adenocarcinoma cell lines, in
cultured normal human small airway epithelial cells (SAEC), one carcinoid cell line, three squamous
cell lines and tissue samples from nine patients with various types of lung cancer. A nuclease
protection assay showed prominent levels of α7 in the NCI-H82 SCLC cell line while α7 was not
detected in SAEC, suggesting that α7 mRNA levels may be higher in SCLC compared to normal
cells. Using a specific antibody to the α7 nicotinic receptor, protein expression of α7 was
determined. All SCLC cell lines except NCI-H187 expressed protein for the α7 receptor. In the
non-SCLC cells and normal cells that express the α7 nAChR mRNA, only in SAEC, A549 and NCI-
H226 was expression of the α7 nicotinic receptor protein shown. When NCI-H69 SCLC cell line
was exposed to 100 pm NNK, protein expression of the α7 receptor was increased at 60 and 150
min.
Conclusion: Expression of mRNA for the neuronal nicotinic acetylcholine receptor α7 seems to
be ubiquitously expressed in all human lung cancer cell lines tested (except for NCI-H441) as well
as normal lung cells. The α7 nicotinic receptor protein is expressed in fewer cell lines, and the
tobacco carcinogen NNK increases α7 nicotinic receptor protein levels.
Background
We and others have shown that one of the mechanisms of
growth regulation of small cell lung cancer (SCLC) cell
lines and cultured pulmonary neuroendocrine cells
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(PNEC) is by the binding of agonists to a cell surface
receptor of the neuronal nicotinic acetylcholine receptor
family comprised of homomeric α7 subunits, which func-
tions as an ion channel with high permeability for Ca2+ [1-
8]. Binding of agonists to this receptor activates the release
of the autocrine growth factor serotonin [2-6]. In addi-
tion, we have shown that the nicotine-derived carcino-
genic nitrosamine, 4(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK), is a high affinity agonist for the α7
nicotinic acetylcholine receptor (α7 nAChR) [5]. Binding
of NNK to this receptor caused an influx of Ca2+ from the
extracellular environment [7], resulting in the activation
of a protein kinase C-dependent Raf-1/MAP kinase-medi-
ated mitogenic pathway [5,9,10]. These findings suggest
that the chronic stimulation of this pathway may contrib-
ute to the selective development of this histologic cancer
type in smokers. Accordingly, components of this signal
transduction pathway may be promising targets for cancer
intervention studies with selectivity for SCLC.
Our goal in the present studies was to determine the
extent of α7 mRNA expression in the human lung to
determine if previous research with SCLC could be extrap-
olated to other lung malignancies. Previous research in
our laboratory indicated expression of mRNA for the α7
receptor in normal fetal hamster PNEC cells [6]. PNEC
cells are one of the possible cells of origin for SCLC
[11,12]. We screened multiple small cell and non-small
cell lung cancer cell lines, normal cells, and fresh surgical
tissue samples from cancer patients for mRNA expression
of the α7 receptor. With the exception of NCI-H441 cell
line, all cell lines and patient samples tested expressed
mRNA for the α7 receptor, and the α7 nicotinic receptor
protein is expressed in fewer cell lines.
Methods
Cell culture
The human SCLC cell lines NCI-H69, NCI-H82, NCI-
H146, NCI-H187, NCI-H209, and NCI-H526, the human
adenocarcinoma cell lines NCI-H322 and NCI-H441, and
A549, the carcinoid cell line NCI-H727, and the squa-
mous cell lines NCI-H226, NCI-H2170, and NCI-H520
were purchased from the American Type Culture Collec-
tion (Manassas, VA). The human SCLC cell line WBA [13]
was a gift of Dr. G. Krystal, Medical College of Virginia. All
cancer cell lines except A549 were maintained in RPMI
medium supplemented with fetal bovine serum (10% v/
v), L-glutamine (2 mM), penicillin (100 U/ml) and strep-
tomycin (100 µg/ml) at 37°C in an atmosphere of 5%
CO2. A549 cells were grown in Hams F12 media with sup-
plements as above. Human small airway epithelia cells
(SAEC) were purchased from Clonetics/BioWhittaker
(Walkersville, MD). These cells were maintained in SAEC
basal medium with supplements (Clonetics) at 37°C in
an atmosphere of 5% CO2. Fresh surgical tissue samples
were collected from patients at the University of Tennes-
see Graduate School of Medicine's Cancer Center and
processed for reverse transcription polymerase chain reac-
tion (RT-PCR). The collection of tissue was approved by
the University of Tennessee Institutional Review Board,
and the authors have been certified by the NIH Office of
Human Subjects Research.
RT-PCR
RT-PCR assays were conducted with all cells and tissues.
Expression of the α7 receptor by RT-PCR in fetal hamster
PNECs has been previously published [6]. RT-PCR was
done as described before [6] except new human α7 prim-
ers (forward 5'-gccaatgactcgcaaccactc-3' and reverse 5'-
ccagcgtacatcgatgtagca-3' bases 236–571, Genbank acces-
sion number X70297) were used. These amplified a 335
bp fragment. Oligonucleotide primers were acquired from
Life Technologies (Grand Island, NY). These primer pairs
are in areas of the sequence that are homologous between
humans, rats, and chick brain [14]. Reactions were run on
a MJ Research PTC-200 thermal cycler (Watertown, MA)
with the following conditions: 1 cycle of 2 min. at 94°C,
40 cycles of 94°C, 30 sec; 55°C, 30 sec; 72°C, 45 sec, with
a final extension for 5 min. at 72°C.
Sequencing
Several PCR products were sequenced to verify the integ-
rity of the PCR process. The NCI-H69, NCI-H322, and
SAE cells were sequenced using the forward PCR primer
for human α7. Sequencing was done with the ABI Termi-
nator Cycle Sequencing reaction kit on an ABI 373 DNA
sequencer (Perkin-Elmer, Foster City, CA).
Nuclease-protection assay
The nuclease protection assay was used to determine dif-
ferences in expression levels in a representative SCLC cell
line (NCI-H82), and in SAE cells. The Lig'nScribe kit
(Ambion, Austin, TX) was used to add a T7 RNA polymer-
ase promoter to the PCR fragment amplified by the gene
specific α7 primer, and then this T7-α7 fragment was PCR
amplified, and the resulting fragment was used directly in
a transcription reaction using the MAXIscript in vitro tran-
scription kit (Ambion). This transcription reaction con-
sisted of the PCR fragment, 10X transcription buffer, 10
mM ATP, UTP and GTP, T7 polymerase, [α-32P] CTP (800
Ci/mmol, Dupont-NEN, Boston, MA), and nuclease free
water to a final volume of 20 µl. A probe for 28S ribos-
omal RNA was also transcribed and used as an internal
control. These reactions were incubated for 1 hour at
37°C. After this incubation, 1 µl of DNase I was added,
and the mixture was further incubated for 15 min. at
37°C. The probes were gel purified.
The RPA III kit (Ambion) was used. A molar excess of
labeled probes (28S and gene specific) were added to 20
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µg total RNA or Yeast RNA (Ambion), and the RNA sam-
ples and probes were co-precipitated and resuspended in
hybridization buffer. After incubation at 95°C for 4 min.,
and incubation overnight at 42°C, RNase digestion buffer
containing RNase A/RNase T1 was added. After digestion
for 30 min. at 37°C, RNase inactivation/precipitation
solution was added. After precipitation the pellets were
resuspended in gel loading buffer, heated at 95°C for 4
min. and loaded onto a 5% polyacrylamide, 8 M urea gel
(Bio-Rad, Hercules, CA). In addition RNA Century Mark-
ers Plus templates (Ambion) were transcribed and used as
markers. After electrophoresis, the gel was transferred to
blotting paper, dried, and exposed to Kodak XAR film.
Western blots
Cell pellets were collected and membrane protein was iso-
lated with the ReadyPrep protein extraction kit (signal)
(Biorad). Protein levels were determined using the RCDC
kit (Biorad). Aliquots of 20–30 µg protein were boiled in
3x loading buffer (New England Biolabs, Beverly, MA) for
2 minutes, then loaded onto 12% Tris-glycine-polyacryla-
mide gels (Cambrex, Rockland, ME), and transferred elec-
trophoretically to nictrocellulose membranes.
Membranes were incubated with the primary antibody
(alpha 7 nicotinic acetylcholine receptor; Abcam, Cam-
bridge, MA). In all western blots, membranes were addi-
tionally probed with an antibody for actin (Sigma) to
ensure equal loading of protein between samples. The
membranes were then incubated with appropriate sec-
ondary antibodies (Rockland, Gilbertsville, PA or Molec-
ular Probes, Eugene OR). The antibody-protein
complexes were detected by the LiCor Odyssey infrared
imaging system (Lincoln, NE). Cells for some blots were
incubated with 100 pM NNK (Midwest Research Institute,
Kansas City, MO) for various times.
Results
The RT-PCR assay demonstrated expression of the α7
nAChR in all seven cultured human SCLC cell lines (Fig-
ure 1) and in SAE cells (Figure 2). Among the two adeno-
carcinoma cell lines, NCI-H322 demonstrated expression
of the α7 nAChR, whereas NCI-H441, yielded negative
results (Figure 3). Both adenocarcinoma cell lines demon-
strated expression of the cyclophilin control indicating
that the α7 nicotinic acetylcholine receptor was either not
expressed in NCI-H441 cells, or expression levels were
Agarose gel showing α7 nicotinic acetylcholine receptor exp e sion in SCLC cell linesFigure 1
Agarose gel showing α7 nicotinic acetylcholine 
receptor expression in SCLC cell lines. cDNA was 
amplified by PCR using the human α7 primers. SCLC cell 
lines: 1) WBA; 2) NCI-H69; 3) NCI-H82; 4) NCI-H146; 5) 
NCI-H187; 6) NCI-H209; 7) NCI-H526. For all gene expres-
sion experiments, negative control reactions were per-
formed and found to be negative. The bands were consistent 
with the expected size, 335 bp. M-100 bp DNA ladder.
Agarose gel showing α7 nicotinic acetylcholine receptor exp e sion in normal small airway epithelial c llsFigure 2
Agarose gel showing α7 nicotinic acetylcholine 
receptor expression in normal small airway epithelial 
cells. cDNA was amplified by PCR using the human α7 and 
cyclophilin primers. 1) α7 primers; 2) cyclophilin primers. 
For all gene expression experiments, negative control reac-
tions were performed and found to be negative. The bands 
were consistent with the expected sizes, 335 bp for the α7 
primers and 216 bp for the cyclophilin primers. M-100 bp 
DNA ladder.
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below the limit of detection of RT-PCR samples run on an
agarose gel.
To verify the RT-PCR results, RT-PCR products from one
SCLC cell line (NCI-H69) and the adenocarcinoma cell
line NCI-H322 were sequenced using the forward primer
used for RT-PCR amplification of the samples (data not
shown). The sequences from the PCR products of both
NCI-H69 and NCI-H322 were compared to the sequence
of the α7 nicotinic acetylcholine receptor (bases 257–571,
Genbank accession number X70297) and were found to
be 100% homologous.
Although we have shown mRNA expression for the α7
nicotinic acetylcholine receptor, it was necessary to show
if expression of the α7 nicotinic acetylcholine receptor
protein in seen in these cell lines. Using a specific anti-
body for the α7 nicotinic acetylcholine receptor (Abcam),
membrane protein from the cell lines were assessed by
western blotting. Expression of α7 protein was seen in 6
of the 7 SCLC cell lines (Figure 4). Expression of α7 pro-
tein was not seen in the NCI-H187 cell line (Figure 4).
Actin levels were unchanged in all 7 SCLC cell lines (Fig-
ure 4).
Additional non-small cell lung cancer cell lines were
screened for the presence of α7 nAChR mRNA expression.
Expression of α7 nAChR was also seen in A549 adenocar-
cinoma and NCI-H727 carcinoid cell lines (Figure 5). The
mRNA for α7 nAChR was also expressed in three squa-
mous cell lines, NCI-H2170, NCI-H226, and NCI-H520
Agarose gel showing α7 nicotinic acetylcholine receptor exp e sion in NCI-H322 but not NCI-H441 adenocarcinoma cell linesFigur  3
Agarose gel showing α7 nicotinic acetylcholine 
receptor expression in NCI-H322 but not NCI-H441 
adenocarcinoma cell lines. cDNA was amplified by PCR 
using the human α7 and cyclophilin primers. 1) NCI-H322, 
α7 primers; 2) NCI-H441, α7 primers; 3) NCI-H322, cyclo-
philin primers; 4) NCI-H441, cyclophilin primers. For all gene 
expression experiments, negative control reactions were 
performed and found to be negative. The bands were con-
sistent with the expected sizes, 335 bp for the α7 primers 
and 216 bp for the cyclophilin primers. M-100 bp DNA 
ladder.
Expression of α7 nicotinic acetylcholine receptor protein in SCLC cell lines as assessed by western blot analysisFigure 4
Expression of α7 nicotinic acetylcholine receptor protein in SCLC cell lines as assessed by western blot analy-
sis. Protein was isolated with the ReadyPrep protein extraction kit (signal) (Biorad). Nitrocellulose membranes were incubated 
with the rabbit polyclonal antibody to the alpha 7 nicotinic acetylcholine receptor (Abcam). 1) WBA; 2) NCI-H69; 3) NCI-
H82; 4) NCI-H146; 5) NCI-H187; 6) NCI-H209; 7) NCI-H526. The arrow indicates the 56 kDa band (expected size). All 
SCLC cell lines except NCI-H187 express protein for alpha 7 nicotinic acetylcholine receptor.
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(Figure 5). Expression of the α7 nAChR was also seen in
nine fresh tissue samples from lung cancer patients, all of
which were smokers (Figure 6).
The non-SCLC cell lines and normal cells were also
screened for expression of α7 nicotinic acetylcholine
receptor protein. SAEC, the adenocarcinoma cell line
A549 and the squamous cell line NCI-H226 express pro-
tein for α7 (Figure 7), whereas the adenocarcinoma cell
line NCI-H322, the carcinoid cell line NCI-H727, the
squamous cell lines NCI-H520 and NCI-H2170 did not
express protein for the α7 nicotinic acetylcholine receptor
(Figure 7). Actin levels were unchanged in all protein sam-
ples (Figure 7).
To allow for a direct comparison of expression levels of α7
mRNA between a representative SCLC cell line (NCI-
H82), and human SAE cells from a non-smoker (informa-
tion provided by Clonetics), a riboprobe was transcribed
from the PCR fragment amplified by the gene specific α7
primer used for RT-PCR and was used in a nuclease pro-
tection assay. Expression of mRNA for the α7 nicotinic
acetylcholine receptor was demonstrated in the SCLC cell
line NCI-H82, however no protected band was detected in
the normal small airway epithelial cells (Figure 8). Expres-
sion of the 28S ribosomal RNA used as an internal control
was seen in both samples (Figure 8). No protected bands
were seen with either probe when annealed to yeast RNA
(Figure 8). The increased levels of α7 nAChR mRNA as
compared with the normal SAE cells suggest that some
SCLC cells may have higher levels of α7 nAChR than nor-
mal lung epithelial cells.
To determine if the α7 nicotinic acetylcholine receptor
protein is a functional protein, we stimulated a represent-
ative SCLC cell line, NCI-H69 with NNK. This cell line
had been used previously in our laboratories to show α7
nicotinic acetylcholine receptor specific binding [5]. The
tobacco carcinogen NNK (100 pM) increased expression
of α7 protein levels after 60 and 150 minutes of treatment
(Figure 9). Actin levels were unchanged between the times
protein was collected (Figure 9).
Discussion
Our data supports the ubiquitous expression of the α7
nAChR mRNA in both normal and cancerous lung cells.
With the exception of the NCI-H441 adenocarcinoma cell
line, the α7 nAChR mRNA was expressed in all normal
and cancer cells tested. Previous research in our laboratory
indicated expression of mRNA for the α7 receptor in nor-
mal fetal hamster PNEC cells [6]. PNEC cells are one of
the possible cells of origin for SCLC [11,12]. The expres-
sion of the α7 nAChR is not an artifact of cell culture since
the expression of the α7 nAChR was seen in nine tumor
samples from different patients with lung cancer. We also
found that the α7 nAChR is expressed in five distinct types
of cancer: squamous, carcinoid, adenocarcinoma, large
cell carcinoma, and small cell lung cancer. This is the first
report of the expression of the α7 nAChR receptor mRNA
Agarose gel showing α7 nicotinic acetylcholine receptor exp e sion in A-549 ade ocarcinoma, NCI-H727 arcinoid, and squamous cell lines NCI-H226, NCI-H520, and NCI-H2170Figure 5
Agarose gel showing α7 nicotinic acetylcholine 
receptor expression in A-549 adenocarcinoma, NCI-
H727 carcinoid, and squamous cell lines NCI-H226, 
NCI-H520, and NCI-H2170. cDNA was amplified by PCR 
using the human α7 primers. 1) A549; 2) NCI-727; 3) NCI-
H226; 4) NCI-H520; 5) NCI-H2170. For all gene expression 
experiments, negative control reactions were performed and 
found to be negative. The bands were consistent with the 
expected size, 335 bp. M-100 bp DNA ladder.
Agarose gel showing α7 nicotinic acetylcholine receptor exp e sion in tissue samples from lung cancer patientsFigure 6
Agarose gel showing α7 nicotinic acetylcholine 
receptor expression in tissue samples from lung can-
cer patients. cDNA was amplified by PCR using the human 
α7 primers. 1) large cell carcinoma; 2) carcinoid; 3–5) squa-
mous cell carcinomas; 6–8) adenocarcinomas; 9) adenocarci-
noma/carcinoid. For all gene expression experiments, 
negative control reactions were performed and found to be 
negative. The bands were consistent with the expected size, 
335 bp. M-100 bp DNA ladder.
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in pulmonary squamous, carcinoids or large cell carcino-
mas. A recent report indicated α7 nAChR receptor mRNA
in both human bronchial epithelial cells and airway
fibroblasts [15], supporting the hypothesis of ubiquitous
expression of the α7 nAChR receptor mRNA in human
lung cells.
In addition, we have demonstrated expression of the α7
nAChR protein of the correct molecular weight in lung
cancer cells for the first time. Of the seven SCLC cell lines
tested for the α7 nAChR mRNA expression, only the NCI-
H187 cell line did not express a band of the correct
molecular weight for the α7 nAChR. In the non-SCLC
cells and normal cells that express the α7 nAChR mRNA,
α7 nAChR protein expression was more limited than in
SCLC. SAEC (normal cells), the adenocarcinoma cell line
A549 and the squamous cell line NCI-H226 express pro-
tein for α7, whereas the adenocarcinoma cell line NCI-
H322, the carcinoid cell line NCI-H727, the squamous
cell lines NCI-H520 and NCI-H2170 did not express pro-
tein for α7. However, our data are in contrast to another
recent study. Carlisle et al. [15] found that α7 nAChR tran-
scripts are frequently found in human bronchial epithelial
cells although the protein of the correct size is not. They
also postulated that muscle-type nicotinic acetylcholine
receptors might be involved in responses to nicotine. Fur-
ther research is needed to determine if both neuronal and
muscle type acetylcholine receptors are involved in signal-
ing events in lung cancer cells.
Previous research from our laboratories has indicated that
NNK binds with high affinity to alpha-bungarotoxin (ago-
nist for α7 and α8 [16]) sensitive nAChRs in NCI-H69
and NCI-H82 cells, and the NNK affinity for these recep-
tors was several times higher than for nicotine [5]. This
binding was inhibited by hexamethonium but not decam-
ethonium [5]. Hexamethonium is a selective agonist for
neuronal nAChRs, whereas decamethonium is selective
for muscle-type nAChRs [17]. In addition, we have found
that NNK activates the Raf-1/MAP kinase pathway result-
ing in phosphorylation of c-myc [10]. This activation was
inhibited by alpha-bungarotoxin. Lending support to this
data, in the present study NNK stimulated α7 protein
expression in NCI-H69 cells. Although muscle type acetyl-
choline receptors may be involved in signaling responses
in SCLC, our data indicates the α7 neuronal nicotinic ace-
tylcholine receptor is a functional receptor in lung cells
and stimulates signaling events in these cells.
Using a nuclease protection assay that allows for direct
comparisons between samples, we found higher levels of
α7 nAChR mRNA receptor in NCI-H82 than in SAEC. The
RT-PCR assay showing expression of α7 nAChR receptor
in SAE cells is a much more sensitive assay, but does not
Expression of α7 nicotinic acetylcholine receptor protein in non-SCLC cell lines and normal SAE cells as assessed by western blot analysisFigure 7
Expression of α7 nicotinic acetylcholine receptor protein in non-SCLC cell lines and normal SAE cells as 
assessed by western blot analysis. Protein was isolated with the ReadyPrep protein extraction kit (signal) (Biorad). Nitro-
cellulose membranes were incubated with the rabbit polyclonal antibody to the alpha 7 nicotinic acetylcholine receptor 
(Abcam). 1) SAEC; 2) A549; 3) NCI-727; 4) NCI-H226; 5) NCI-H520; 6) NCI-H2170; 7) NCI-H322. The arrow indicates the 
56 kDa band (expected size). Only SAEC, A549 and NCI-H226 express protein for alpha 7 nicotinic acetylcholine receptor.
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allow for the comparisons seen in the nuclease protection
assay. The increase in α7 nAChR receptor in the SCLC cell
line NCI-H82 compared to the normal SAE cells from a
non-smoker is consistent with other data from our labo-
ratory and others. In addition, it has been shown that the
NCI-H82 cell line synthesized the highest levels of acetyl-
choline, and addition of nicotinic antagonists slowed
growth of the NCI-H82 cells [18]. Acetylcholine is known
to act as an autocrine growth factor for SCLC [19]. This
data is also consistent with protein levels of the α7
nAChR. The NCI-H82 cell line had the highest level of α7
nAChR protein of the SCLC cell lines tested.
Treatment of pregnant hamsters with the tobacco carcino-
gen, NNK, led to an increase in the α7 nAChR in PNEC
isolated from fetal hamsters on the 15th day of gestation
[20]. As indicated above, previous data from our labora-
tory has also shown that an associated mitogenic signal
transduction pathway is upregulated in SCLC. Similar
results were seen in the hamster PNEC model, as protein
levels of Raf-1 in NNK treated hamster PNEC were greatly
increased compared to control PNEC protein levels, and
the NNK treated PNEC protein levels were at similar levels
to untreated SCLC cell line NCI-H69 cells [9,10]. In addi-
tion, ERK1/2 protein levels were also increased in NNK
treated PNEC [9,10]. These findings are in accord with
publications which have demonstrated that chronic
exposure of brain cells to nicotinic agonists results in a
paradoxical upregulation of this receptor [17,21-23]. Our
findings are also supported by a study in monkeys, which
has shown that chronic treatment of pregnant monkeys
with nicotine caused a pronounced upregulation of the
α7 nAChR in the lungs of the newborns [24]. Together
these data indicate that the α7 nAChR may play an impor-
tant role in the development of SCLC, and other lung can-
cers in which smoking is involved. Although there are
many growth factors involved in multiple pathways lead-
ing to lung cancer, the effects of signaling through nico-
tinic receptors needs further investigation to determine its
role in the pathogenesis of lung cancer. Further studies
with lung cancer cell lines that express both the mRNA
and protein for the α7 nAChR are needed.
Conclusion
Expression of mRNA for the neuronal nicotinic acetylcho-
line receptor α7 seems to be ubiquitously expressed in all
human lung cancer cell lines tested (except for NCI-H441)
as well as normal lung cells. The α7 nicotinic receptor pro-
tein is expressed in fewer cell lines, and the tobacco carcin-
ogen NNK increases α7 nicotinic receptor protein levels.
The α7 nAChR may play an important role in the develop-
ment of SCLC and other lung cancers in which smoking is
involved.
Comparison of expression levels of α7 nicotinic acetylcho-line receptor between a representative SCLC cell line (NCI-H82), nd SAE cells by ucl ase protecti n ass yFigure 8
Comparison of expression levels of α7 nicotinic ace-
tylcholine receptor between a representative SCLC 
cell line (NCI-H82), and SAE cells by a nuclease pro-
tection assay. A riboprobe transcribed from the human α7 
PCR primer was used to compare expression levels in the 
two cell systems. 1) NCI-H82; 2) SAEC; 3) Yeast RNA. The 
protected fragments were consistent with the expected 
sizes, 335 bp for the α7 primers and 115 bp for the 28S 
ribosomal RNA control primers. The molecular weight 
markers are indicated by the numbers on the left side of the 
figure.
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Increases in expression of α7 nicotinic acetylcholine receptor protein in NCI-H69 after treatment with 100 pM 
of the tobacco carcinogen NNK as assessed by western blot analysis. Protein was isolated with the ReadyPrep pro-
tein extraction kit (signal) (Biorad). Nitrocellulose membranes were incubated with the rabbit polyclonal antibody to the alpha 
7 nicotinic acetylcholine receptor (Abcam). 1) control; 2) 5 min; 3) 30 min; 4) 60 min; 5) 150 min; 6) 24 hour. The arrow indi-
cates the 56 kDa band (expected size). Increases were seen in expression of protein for alpha 7 nicotinic acetylcholine recep-
tor after 60 min and 150 min of NNK treatment.
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